The National Cancer Institute this month plans to revisit itscontroversial decision not to recommend mammography screeningfor women aged 40 to 49. The NCI is scheduled to hold a consensusdevelopment conference on the topic Jan. 21-23 in Bethesda, MD.The
The National Cancer Institute this month plans to revisit itscontroversial decision not to recommend mammography screeningfor women aged 40 to 49. The NCI is scheduled to hold a consensusdevelopment conference on the topic Jan. 21-23 in Bethesda, MD.
The NCI in 1993 withdrew its recommendation that women aged 40to 49 receive screening mammograms every one to two years (SCAN12/15/93). The move conflicted with screening guidelines fromgroups such as the American College of Radiology and AmericanCancer Society, and drew heavy criticism.
Several studies have been published since then suggesting thatmammography screening of younger women could reduce the deathrate from breast cancer. This month's conference will review thosedata, and will examine whether or not the NCI's guidelines shouldbe changed accordingly, an NCI spokesperson said.
The conference will take place at the Natcher Conference Centerat the National Institutes of Health, Building 45, 9000 RockvillePike, Bethesda. For registration information contact Hope LevyKott at Technical Resources International, 301/468-2245.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.